Redeye comments on today’s news from Thunderful Group, which includes a SEK50m directed share issue,...
Redeye views the recently announced progress on US reimbursements positively, as a second payor has ...
Adtraction redovisade minskad nettoomsättning och EBITA i det andra kvartalet.
Mendus has fortified its intellectual property (IP) profile for lead candidate, vididencel, with the...
NoHo Partners will publish its Q2 2025 results on 5 August, at around 8:00 EET.
Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech...
Lower sales but demand for shore power solid Cavotec reported sales of EUR 36m (17% below our estima...
Vaisala’s Q2 fell short of our estimates due to weaker than expected performance in W&E.
Physitrack delivered a solid Q2, highlighted by margin expansion, positive free cash flow, and great...
Redeye makes rather small, but positive, changes to our financial forecasts on the back of strong Q2...
Redeye updates its forecast and valuation following Modelon’s Q2 2025 report, which came broadly in ...
Soft Q2, but heading in the right direction We forecast Q2 sales of EUR 27.
W&E headwinds had a greater impact than we anticipated in Q2, resulting in net sales coming in sligh...
India returns to growth and margins expand Medicover delivered another strong quarter, beating adj.
Safello has announced a partnership with Marginalen Bank, positioning itself as the first crypto bro...
Stronger order intake, but lower sales Cavotec reported order intake of EUR 44m (+7% vs.
Redeye notes that Gapwaves' Q2 2025 report exceeded its estimates on all key metrics.
Net sales and clean EBIT were below market consensus (LSEG) in Q2.
Redeye updates its estimates and valuation following MedCap’s Q2 2025 report.
Redeye comments on Polygiene Group´s Q2 2025. Polygiene Group delivered negative growth of -12% y/y.
